8-K: Tharimmune Secures $2.02 Million in Private Placement to Fuel Clinical Programs

Tharimmune, a clinical-stage biotech firm, has successfully raised approximately $2.02 million through a private placement to advance its clinical development programs.

Summary

• Tharimmune, Inc. has entered into a securities purchase agreement for a private placement, raising approximately $2.02 million.
• The private placement includes the issuance of 961,446 shares of common stock or common stock equivalents, along with warrants to purchase an additional 480,723 shares.
• Each share or equivalent is priced at $2.10, and each comes with a warrant.
• The warrants have an exercise price of $2.031 per share and become exercisable six months after issuance, expiring five and a half years from the issuance date.
• The closing of the transaction is expected around December 9, 2024, subject to standard closing conditions.
• The financing was led by Gravitas Capital and SDS Capital Group, with participation from other biotech-focused private investors.
• President Street Global acted as the exclusive placement agent for the offering.
• The net proceeds will be used for clinical development, including advancing the TH104 program, and for general working capital.

Sentiment

Score: 7

Explanation: The document is positive as it details a successful capital raise, which is crucial for a clinical-stage biotech company. The funds are earmarked for key development programs, indicating a positive outlook for the company's future.

Positives

• The successful private placement provides Tharimmune with $2.02 million in gross proceeds.
• The funds will be used to advance clinical development programs, particularly the TH104 program.
• The financing was supported by strategic investors, including Gravitas Capital and SDS Capital Group.
• The company has secured a placement agent to ensure a smooth transaction.

Risks

• The securities offered in the private placement are not registered under the Securities Act or state securities laws.
• The company's future performance is subject to risks outlined in their SEC filings.
• The company may not achieve the plans, intentions, or expectations disclosed in forward-looking statements.

Future Outlook

The company intends to use the net proceeds to advance its clinical development programs, particularly TH104, and for general working capital. They also plan to file a resale registration statement to enable future trading of the securities.

Management Comments

• Tharimmune is committed to pioneering therapies in immunology and inflammation.
• The financing reinforces Tharimmune's commitment to advancing its portfolio of therapeutic candidates.

Industry Context

This private placement is a common method for clinical-stage biotechnology companies to raise capital for research and development. The focus on immunology and inflammation aligns with current trends in the biotech industry.

Comparison to Industry Standards

• The use of a private placement to raise capital is a standard practice for biotech companies, especially those in the clinical stage like Tharimmune.
• The terms of the warrants, with a six-month waiting period before exercisability and a five-and-a-half-year expiration, are fairly typical in such financings.
• The involvement of specialized investors like Gravitas Capital and SDS Capital Group is common in biotech private placements, as these firms often have a deeper understanding of the industry and its risks.
• The use of President Street Global as a placement agent is also a standard practice, as they have experience in facilitating such transactions.

Stakeholder Impact

• Shareholders will see the company's financial position strengthened.
• Employees will benefit from the continued funding of research and development.
• Customers (potential patients) may benefit from the advancement of new therapies.
• Creditors may see the company as a more stable entity due to the capital raise.

Next Steps

• The company will close the private placement on or about December 9, 2024.
• Tharimmune will allocate the net proceeds to clinical development and working capital.
• The company will file a resale registration statement for the securities.
• The company will seek to list the shares and warrant shares on the Nasdaq.

Key Dates

Keywords

private placement, biotechnology, clinical development, TH104, warrants, common stock, immunology, inflammation, financing, capital raise